ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Market Capitalization on January 14, 2025: USD 3.74 M

ZyVersa Therapeutics, Inc. Market Capitalization is USD 3.74 M on January 14, 2025, a -69.16% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

ZyVersa Therapeutics, Inc. 52-week high Market Capitalization is USD 19.26 M on February 29, 2024, which is 415.35% above the current Market Capitalization.
ZyVersa Therapeutics, Inc. 52-week low Market Capitalization is USD 2.34 M on December 03, 2024, which is -37.36% below the current Market Capitalization.
ZyVersa Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 8.81 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years